Nigel Lange - Sirtex Medical CEO of Europe

SRX -- Australia Stock  

AUD 33.55  0.00  0.00%

Mr. Nigel Lange is Chief Commercial Officer of the Company effective 5 June, 2017. He joined Sirtex US in 2002, then set up Sirtex operations in Europe. Before joining Sirtex, Mr Lange held senior roles at Nordion Inc and has over 20 years of experience in the healthcare industry. Mr Lange is based in our regional office in Bonn, Germany, where he is responsible for the development and execution of the strategic direction of sales and marketing in Europe as well as the Middle East and Africa, a region which for Sirtex comprises a total of 20 countries with direct sales and distributor sales models.
  CEO Since 2017      
61 2 9964 8400

Management Efficiency

The company has return on total asset (ROA) of 17.25 % which means that it generated profit of $17.25 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 26.87 % meaning that it generated $26.87 on every $100 dollars invested by stockholders.

Entity Summary

Sirtex Medical Limited, a life-sciences company, develops and delivers oncology treatments using novel small particle technology in the Asia-Pacific, Europe, the Middle East, Africa, and North and South America. As of September 20, 2018, Sirtex Medical Limited operates as a subsidiary of CDH Genetech Limited. Sirtex Medical operates under Biotechnology classification in Australia and is traded on Australian Securities Exchange.Sirtex Medical Limited (SRX) is traded on Australian Securities Exchange in Australia and employs 292 people.

Sirtex Medical Leadership Team

Darren Smith, CFO, Company Secretary
Richard Hill, Non-Executive Chairman of the Board
Neville Mitchell, Independent Non-Executive Director
Gilman Wong, CEO, Managing Director and Executive Director
Tom Duthy, Global Investor Relations Manager
Michael Mangano, President of Americas Region
Katherine Woodthorpe, Non-Executive Independent Director
Nigel Lange, CEO of Europe
John Eady, Non-Executive Deputy Chairman of the Board
Anthony Dixon, Executive Vice President of Sales and Marketing,EMEA
Robert Hardie, Global Head of Operations
Helen Kurincic, Independent Non-Executive Director
Kevin Richardson, CEO, Americas
Rueben Teo, CEO, Asia Pacific (APAC)
David Cade, Global Medical Director
Andrew McLean, CEO, Executive Director
Grant Boyce, Non-Executive Director

Stock Performance Indicators

Current Sentiment - SRX

Sirtex Medical Investor Sentiment

Most of Macroaxis users are at this time bullish on Sirtex Medical Limited. What is your outlook on investing in Sirtex Medical Limited? Are you bullish or bearish?
98% Bullish
2% Bearish
Currently Active Assets on Macroaxis
Purchased over 40 shares of
2 days ago
Traded for 66.04
Purchased over 70 shares of
2 days ago
Traded for 36.92
Purchased few shares of
2 days ago
Traded for 173.44
Purchased few shares of
2 days ago
Traded for 173.44
Purchased over 70 shares of
2 days ago
Traded for 36.92
Also please take a look at World Market Map. Please also try Financial Widgets module to easily integrated macroaxis content with over 30 different plug-and-play financial widgets.